BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 29753773)

  • 1. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
    Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
    Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
    Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
    Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA
    Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
    Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
    Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
    Hu X; Zhao H; Wang Y; Liu Z; Feng B; Tang C
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3385-3390. PubMed ID: 30197029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity, Docking Study of New Fluorinated Fused Pyrimidine Scaffold: Thermal and Microwave Irradiation Synthesis.
    Alnaja AMA; Farghaly TA; El-Zahabi HSA; Shaaban MR
    Med Chem; 2021; 17(5):501-518. PubMed ID: 31840613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
    Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
    Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazo[1,2-c]pyrimidin-5(6H)-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring.
    Ajani H; Jansa J; Köprülüoğlu C; Hobza P; Kryštof V; Lyčka A; Lepsik M
    J Mol Recognit; 2018 Sep; 31(9):e2720. PubMed ID: 29687635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
    Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and anticancer evaluation of novel pyrazole, pyrazolo[3,4-d]pyrimidine and their glycoside derivatives.
    Nassar IF; El Farargy AF; Abdelrazek FM; Ismail NSM
    Nucleosides Nucleotides Nucleic Acids; 2017 Apr; 36(4):275-291. PubMed ID: 28323527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W
    Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.
    Hassan GS; Abdel Rahman DE; Nissan YM; Abdelmajeed EA; Abdelghany TM
    Eur J Med Chem; 2017 Sep; 138():565-576. PubMed ID: 28704759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.